Is Turmesac® safe?
Preclinical studies reported no mortality at a single oral dose of 2,000 mg/kg and no Turmesac®-related toxic effects during a 28-day study at doses up to 1,000 mg/kg/day.
Research / Safety
Safety Profile & Toxicology
Turmesac® is a full-spectrum phytochemical composition derived from turmeric rhizome and manufactured by Star Hi Herbs Pvt. Ltd. Its safety has been evaluated through acute and repeated-dose preclinical toxicity studies, with no mortality or Turmesac®-related toxic effects at the tested doses.
01 / Acute
Acute oral toxicity
2,000mg/kg highest tested single dose
0Mortality reported
5Dose levels evaluated
NormalBody weight and intake
Turmesac® was evaluated at oral doses of 50, 250, 500, 1,000 and 2,000 mg/kg body weight. At the highest tested dose of 2,000 mg/kg:
- No acute toxic symptoms were observed
- No mortality occurred
- Body weight remained within the normal range
- Food and water intake remained normal
- No abnormal clinical signs were reported
- Relative organ weights showed no Turmesac®-related changes
02 / Sub-acute
28-day repeated-dose toxicity
A sub-acute toxicity study evaluated daily oral administration of Turmesac® at 250, 500 and 1,000 mg/kg body weight per day for 28 days. No Turmesac®-related toxic effects were detected at any tested dose. Evaluated safety parameters included:
- General behaviour and clinical signs
- Mortality
- Body-weight development
- Food and water consumption
- Relative organ weights
- Hematological parameters
- Biochemical parameters
- Gross and microscopic organ histopathology
The treated groups showed no significant differences from the control group. Histopathological examination found normal tissue architecture in the evaluated organs. These findings support a broad preclinical safety margin across the tested dose range.
03 / Cellular
Cellular safety observations
Additional in-vitro studies provide supportive cellular safety information, although they do not replace formal toxicology testing.
In-vitro studies on MCF-7 (breast cancer cell line) and HeLa (cervical cancer cell line) showed efficient anticancer activity of Turmesac®, with IC₅₀ values of 163.19 µg/mL and 115.12 µg/mL respectively. A dose-dependent decrease in cell viability was reported for both cell lines upon treatment with Turmesac®.
04 / Quality
Heavy metals and contaminants
Specification limits and batch-testing results for lead, arsenic, cadmium, mercury, pesticide residues, aflatoxins, microbiological contaminants and residual solvents are provided from the current specification sheet and batch-specific Certificate of Analysis on request.
05 / Regulatory
Regulatory considerations
Turmesac® is intended for use as an ingredient in appropriately formulated products. The information on this page summarizes preclinical research and does not establish that Turmesac® diagnoses, treats, cures or prevents any disease. Safety, permitted use levels, labelling and claims must be assessed according to the regulations of each destination market.
06 / FAQ
Safety questions
Does Turmesac® have known side effects?
No Turmesac®-related toxic effects were reported in acute and 28-day animal studies. The available evidence is preclinical and does not establish the incidence of side effects in humans.
Request the Turmesac® safety and technical dossier
Toxicology reports, specifications and regulatory documentation are available to qualified partners.